APTA vs. FUM, OKYO, SAR, AOR, OPTI, POLB, IMM, AREC, RLM, and NSCI
Should you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include Futura Medical (FUM), OKYO Pharma (OKYO), Sareum (SAR), AorTech International (AOR), OptiBiotix Health (OPTI), Poolbeg Pharma (POLB), ImmuPharma (IMM), Arecor Therapeutics (AREC), Realm Therapeutics (RLM), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.
Aptamer Group vs.
Futura Medical (LON:FUM) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.
Futura Medical has higher revenue and earnings than Aptamer Group. Futura Medical is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, Futura Medical's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.
35.7% of Futura Medical shares are owned by institutional investors. Comparatively, 11.7% of Aptamer Group shares are owned by institutional investors. 32.1% of Futura Medical shares are owned by insiders. Comparatively, 13.2% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Futura Medical received 186 more outperform votes than Aptamer Group when rated by MarketBeat users.
Futura Medical has a net margin of -44.64% compared to Aptamer Group's net margin of -343.95%. Futura Medical's return on equity of -56.44% beat Aptamer Group's return on equity.
Futura Medical has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Aptamer Group has a beta of -0.52, meaning that its share price is 152% less volatile than the S&P 500.
Summary
Futura Medical beats Aptamer Group on 10 of the 12 factors compared between the two stocks.
Get Aptamer Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptamer Group Competitors List
Related Companies and Tools
This page (LON:APTA) was last updated on 5/2/2025 by MarketBeat.com Staff
